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013.05.0Abstract Introduction and objectives: Cardiovascular disease and its associated comorbidities,
including diabetes mellitus, obesity and dyslipidemia, represent a signiﬁcant socioeconomic burden,
particularly in low- to middle-income countries. Pharmacological intervention with statins, which
reduce low-density lipoprotein–cholesterol levels, has been demonstrated to reduce cardiovascular
risk. This study assessed the prevalence of lipid abnormalities as well as risk factors for dyslipidemia
in Egyptian patients on chronic statin treatment.
Methods: DYSIS is a cross-sectional, observational, multinational study. Key eligibility criteria
were age of at least 45 years and stable statin treatment for at least three months. In the Egyptianernational Cardioscan Center,
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224 A. El Etriby et al.DYSIS cohort, a total of 1466 patients, 920 men and 532 women, were enrolled in 24 different cen-
ters. Patient characteristics and lipid measurements were documented, and multivariate regression
modeling was used to assess factors associated with dyslipidemia.
Results: Most patients (85%) were deﬁned as being at very-high risk of cardiovascular disease.
Gender-speciﬁc differences included higher rates of tobacco smoking and metabolic syndrome in
men and women, respectively. Goal LDL–C levels were not achieved by 67.2% of the population,
rising to 72% in both high- and very-high risk patients. Factors independently associated with
LDL–C levels not being at goal included diabetes mellitus, ischemic heart disease, and high blood
pressure.
Conclusions: Despite chronic statin treatment, two-thirds of patients in the DYSIS-Egypt study
had elevated LDL–C levels. A dual strategy, comprising modiﬁcation of lifestyle factors together
with novel treatment options, appears to be necessary to combat the rise in cardiovascular-related
morbidity and mortality.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Cardiovascular diseases (CVDs), in particular coronary heart
disease and stroke, represent the leading cause of mortality
worldwide. The World Health Organization (WHO) estimates
that in 2008, CVD accounted for over 30% of global deaths;
however, the burden of CVD is not equally distributed, with
over 80% of CVD-related mortality occurring in low- to mid-
dle-income countries.1,2 In Egypt, which is classiﬁed as a lower
middle-income country, 39% of all deaths were caused by
CVD in 2008.3
Despite the fact that CVD is largely preventable and the
risk factors for CVD are well established, rates of CVD-related
morbidity and mortality continue to rise, fueled by lifestyle
changes associated with urbanization and industrialization.1,2,4
Key risk factors for CVD include tobacco smoking, alcohol
consumption, a sedentary lifestyle and poor diet, as well as
concomitant disorders such as high blood pressure, diabetes
mellitus, dyslipidemia and obesity.4,5 In a screening study
assessing cardiovascular risk factors in over 6000 Egyptian
adults, almost one-third (29%) had central obesity, while ﬁg-
ures from the WHO suggest that 35% of Egyptian men are
daily tobacco smokers, and 35% of the Egyptian population
have high blood pressure.3,5,6 Furthermore, data from a study
in Egyptian adolescents demonstrated that 16.4% displayed
pre-diabetes and 6% had raised total cholesterol levels, high-
lighting the potential need for early screening for cardiovascu-
lar risk factors.7
Over the last decade, the use of statins, LDL–cholesterol
(C)-lowering agents, has emerged as a ﬁrst-line pharmacologi-
cal strategy to reduce cardiovascular risk.8–10 The incidence of
lipid abnormalities and cardiovascular events in statin-treated
patients has been monitored in many large randomized studies
and it is estimated that every 1 mmol/l (38.7 mg/dl) reduction
in LDL–C levels confers a 23% reduction in CVD risk.11–14
The recently published JUPITER study, which assessed the
beneﬁt-risk proﬁle of statins in primary prevention, indicated
that in patients with at least one risk factor for diabetes melli-
tus, statin treatment was associated with a 39% reduction in
the primary endpoint of myocardial infarction, stroke, admis-
sion to hospital for unstable angina, arterial revascularization
or cardiovascular death.15
The DYSlipidemia International Study (DYSIS) was a
cross-sectional, observational, multinational study involvingpatients on chronic statin therapy. The aims of the DYSIS
study were to determine the prevalence of lipid abnormalities
in patients on chronic statin therapy, and to better characterize
factors associated with dyslipidemia. Results from the Cana-
dian and European DYSIS cohorts, which included over
22,000 patients, have been previously reported.16 This report
describes the DYSIS-Egypt study.
2. Materials and methods
2.1. Study design and patients
DYSIS was an international, epidemiologic, cross-sectional,
observational study. The Egyptian cohort comprised 1466 pa-
tients (920 men, 532 women) documented by 24 physicians spe-
cialized in cardiology/internal medicine that were distributed
throughout Egypt. Data were collected between December
2011 and April 2012 in local-language case report forms and
held at the Institut fu¨r Herzinfarktforschung Ludwigshafen,
Germany. Prior to study initiation, the relevant local ethics re-
view committees approved the study protocol and patients’ in-
formed consent was obtained. All patients were at least
45 years of age and had been on stable statin treatment for
at least three months.
2.2. Data collection
Information was collected on patients’ demographics (age, sex,
ethnicity), tobacco smoking, lipid levels (LDL–C, high-density
lipoprotein–cholesterol [HDL–C], triglycerides and total cho-
lesterol), family history of CVD, as well as established diagno-
ses of CVD, diabetes mellitus, metabolic syndrome, obesity
and hypertension. For patients with diabetes mellitus, fasting
plasma glucose and HbA1c levels were obtained. Lipid param-
eters were taken from the most recent blood sample within the
last 6–12 months. Details of the name and daily dose of statin,
as well as other lipid-modifying treatments, at the time of the
most recent blood sample were recorded. A potency calcula-
tion was used to normalize dose levels of different statins. Sta-
tin potency was benchmarked against six simvastatin dose
levels (5, 10, 20, 40, 80 and 160 mg/day), with a score of one
being the lowest dose potency equivalent to 5 mg/day of sim-
vastatin) and a score of six being the highest dose potency
(equivalent to 160 mg/day of simvastatin).17,18
Table 1 Patient characteristics, risk categories and lipid parameters.
All patients (n= 1466) Men (n= 920) Women (n= 532)
Age (years) [mean ± SD] 58.0 ± 8.5 57.4 ± 8.3 59.1 ± 8.8
Arabic (%) 95.2 94.9 95.7
Family history of premature CHD (%) 33.8 35.7 30.9
Current smokers (%) 21.8 32.1 4.3
Hypertension (%) 77.8 74.1 84.2
Systolic BP (mmHg) [mean ± SD] 136.9 ± 17.8 135.8 ± 17.7 139.0 ± 17.9
Diastolic BP (mmHg) [mean ± SD] 83.5 ± 10.6 83.1 ± 10.5 84.2 ± 10.8
Waist circumference (cm) [mean ± SD] 103.1 ± 14.0 103.5 ± 14.3 102.3 ± 13.6
BMI (kg/m2) [mean ± SD] 32.3 ± 6.3 31.2 ± 5.8 34.3 ± 6.7
BMI P30 kg/m2 (%) 61.5 54.3 73.7
CVD (%) 65.6 73.9 51.9
Diabetes mellitus (%) 53.6 50.1 59.0
Metabolic syndrome (IDF) (%) 74.7 65.4 90.7
ESC risk level (2011)19
Very high risk patient (%) 85.0 89.6 77.1
High risk patient (%) 2.9 3.3 2.4
Moderate risk patient (%) 8.2 6.4 11.5
Low risk patient (%) 3.8 0.8 9.0
Lipids
LDL–C (mmol/L) [mean ± SD] 2.9 ± 1.1 2.9 ± 1.1 3.0 ± 1.1
HDL–C (mmol/L) [mean ± SD] 1.1 ± 0.3 1.1 ± 0.3 1.2 ± 0.3
Total cholesterol (mmol/L) [mean ± SD] 5.0 ± 1.3 4.9 ± 1.3 5.1 ± 1.2
Triglycerides (mmol/L) [median (IQR)] 1.6 (1.2–1.9) 1.6 (1.2–2.0) 1.5 (1.1–1.9)
Blood glucose
Fasting plasma glucose (mmol/L) [median (IQR)] 6.4 (5.3–8.1) 6.4 (5.2–8.2) 6.6 (5.4–8.0)
HbA1c [%] in diabetic patients [median (IQR)] 7.8 (7.0–8.8) 7.8 (7.0–8.8) 7.9 (7.0–9.0)
Abbreviations: CHD, coronary heart disease; BP, blood pressure; BMI, Body mass index; CVD, cardiovascular disease; DM, diabetes mellitus;
IDF, International Diabetes Federation; IQR, interquartile range; SD, standard deviation; HbA1c, glycosylated hemoglobin A1c; LDL, low
density lipoprotein; HDL, high density lipoprotein.
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The 2011 version of the European Society of Cardiology (ESC)
guidelines was used to deﬁne cardiovascular risk and abnor-
malities in LDL–C, HDL–C and triglyceride levels.19 LDL–
C level treatment goals were LDL <3.0 mmol/L in patients
with SCORE risk 1–4%, LDL <2.5 mmol/L in patients with
SCORE risk 5–9%, LDL <1.8 mmol/L in patients with
CVD, DM, and/or SCORE riskP10%. In general a treatment
target is also met when LDL–C reduction isP50% in case tar-
get levels cannot be reached but this was not considered be-
cause pre-treatment LDL–C values were not available.
Multivariate logistic regression was performed to identify fac-
tors independently associated with lipid abnormalities. Vari-
ables included in the analysis were: age, sex, ﬁrst-grade
family history of premature CVD, current tobacco smoker,
sedentary lifestyle, alcohol consumption (>2 units/week),
body mass index (BMI) P30 kg/m2 (i.e., obesity), large waist
circumference (>102 cm in men, >88 cm in women), history
of hypertension, diabetes mellitus, ischemic heart disease, cere-
brovascular disease, heart failure, peripheral artery disease,
high blood pressure (systolic/diastolic P140/90 mmHg), sim-
vastatin equivalent dose of either 20 to 40 mg/day vs. 10 mg/
day or >40 mg/day vs. 10 mg/day, and ezetimibe.2.4. Statistical analysis
To estimate the sample size needed for Egypt we assumed a
prevalence of lipid abnormalities between 20% and 60% anda design effect of 20% (variance inﬂation due to cluster sam-
pling design). We calculated that, within this range, a sample
size of 1500 would be sufﬁcient to estimate the prevalence with
a given precision of ±2.8% (range of 95% conﬁdence interval
5.6%). Furthermore we determined that this size guaranteed
enough information for estimating the prevalence in smaller
subgroups (representing one quarter or more of the popula-
tion) with a precision of ±5.6% (range of 95%-CI: 11.1%).
Data were entered into a central electronic (web-based)
database housed after the original data were collected on paper
based CRFs and managed at the Institut fu¨r Herzinfarktfors-
chung, Ludwigshafen, Germany, after original data were ﬁrst
collected in paper CRF form. Real-time quality control (inter-
nal logic checks) occurred during web-based data entry.
Continuous variables were presented as means with stan-
dard deviations or medians with 25th and 75th percentiles
(interquartile range [IQR]), as appropriate. Categorical vari-
ables were reported as absolute numbers and percentages.
Kernel density estimation was used to analyze the distribu-
tion of total cholesterol, LDL–C, HDL–C, and triglyceride
levels. The value of a kernel density and its slope at the lipid
value equal to the ESC goal provides a crude indicator of
the change in the proportions of patients meeting the goal
from an improvement or deterioration in lipid level by a small
amount starting from the ESC goal and thus provides a sensi-
tivity analysis for either changes in the ESC goals or changes in
lipid levels for people whose levels are near the goals. For each
kernel density, the mode of the kernel density is in the region
that meets the goal, but quite close to the cut point, so that
deterioration in levels (or raising the goal) of any of the lipids
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Figure 1 Statin dose potency according to patients’ risk status (a) and overall (b) calculated according to17,18 \ Statin dose potency 1 is
equivalent to simvastatin 5 mg/day, potency 2 is equivalent to simvastatin 10 mg/day, potency 3 is equivalent to simvastatin 20 mg/day,
potency 4 is equivalent to simvastatin 40 mg/day, potency 5 is equivalent to simvastatin 80 mg/day, and potency 6 is equivalent to
simvastatin P160 mg/day.
226 A. El Etriby et al.local to the cut point would reduce the proportion meeting
goal by a relatively large and increasing amount as successive
changes in the lipid level approached the mode. Given that the
mode for each meets the goal, an improvement in lipid levels
that are local to the cut point that represents the goal have nec-
essarily smaller effects than a deterioration in lipid levels.
Multiple logistic regression analysis with backward selec-
tion (a= 0.05) was performed to detect factors independently
associated with LDL–C, HDL–C, and triglyceride abnormali-
ties, with variables including patient characteristics, risk cate-
gories, medical history, statin use, and physician’s specialty.
All statistical comparisons were two-tailed, and a p< 0.05
was considered signiﬁcant. Patients who did not have the
appropriate lipid parameters were not included in the lipid
analyses. All analyses were performed using SAS version 9.1
(SAS Institute Inc., USA).3. Results
3.1. Patient characteristics
Patient characteristics, CVD risk categories and lipid parame-
ters are displayed in Table 1. The mean patient age was
58.0 years (men 57.4 years, women 59.1 years), almost all of
the study population was Arabic (95.2%), and over three-
quarters of patients (85.0%; men 89.6%, women 77.1%) were
considered to be at very high risk of CVD (deﬁned as having
CVD, diabetes, and/or an ESC Systematic Coronary Risk
Evaluation [SCORE] risk of P10%). Established CVD was
more common in men (73.9%) than women (51.9%), but met-
abolic syndrome, obesity and diabetes mellitus (type not spec-
iﬁed) were all more frequent in women (90.7%, 73.7% and
Table 2 Lipid abnormalities according to ESC guidelines (2011).
Patients with total
lipid proﬁle
All patients
(n= 1239)
Very high riska
(n= 1048)
High risk
(n= 39)
Moderate risk
(n= 107)
Low risk
(n= 45)
LDL–C not at target
[%]b
67.2 71.7 71.8 49.5 e
Low HDL–C
(<1.0 [men]/1.2 [women]
mmol/L) [%]
46.9 48.0 41.0 41.1 40.0
Elevated TG
(>1.7 mmol/L) [%]
37.3 37.5 35.9 39.3 28.9
All patients (n= 1458) (n= 1,40) (n= 43) (n= 120) (n= 55)
LDL–C not at target
[%]b,c
66.3 70.8 71.8 49.1 e
Low HDL–C
(<1.0 [men]/1.2
[women] mmol/L)
[%]c
45.6 46.3 41.0 41.8 39.6
Elevated TG
(>1.7 mmol/L)
[%]d
37.0 37.1 37.2 39.5 27.1
a Very high risk = CVD, Diabetes, and/or SCORE risk P10% (chronic kidney disease was not documented in DYSIS).
b LDL P3.0 mmol/L in patients with SCORE risk 1–4%, LDL P2.5 mmol/L in patients with SCORE risk 5–9%, LDL P1.8 mmol/L in
patients with CVD, DM, and/or SCORE risk P10%; data on 2,020 patients were available for ‘‘all patients’’.
c Data on 2,165 patients were available,
d Data on 2,166 patients were available.
e In the ESC 2011 guidelines, no LDL–C goal was speciﬁed for the low risk group.
Egyptian patients on chronic statin treatment 22759.0%, respectively, vs. 65.4%, 54.3% and 50.1%, respec-
tively, in men). Tobacco smoking was substantially more pre-
valent in men (32.1%) than women (4.3%), while hypertension
was 10% more frequent in women (84.2% vs. 74.1%) than in
men.
3.2. Lipid-modifying therapies and statin potency
The most commonly prescribed statin was atorvastatin
(43.2%), followed by simvastatin (31.0%), rosuvastatin
(19.4%), ﬂuvastatin (5.3%), pravastatin (1.0%) and lovastatin
(0.2%). Almost one-third of patients (30%) were receiving
other lipid-lowering therapies, primarily ezetimibe (23.7%),
but also ﬁbrates (8.3%), bile acid sequestrants (1.0%) and nic-
otinic acid (0.3%).
Fig. 1a and b demonstrate that statin dose potencies of 3
and 4 were being used by most patients (70.3%), with 40%
of those not being at very high risk on a dose potency of 3
and 40% of very-high risk patients on a dose potency of 4. Sta-
tin dose potencies of 1, 2, 5 and 6 were being taken by 0.6%,
5.6%, 19.8% and 3.8% of patients, respectively.
3.3. Lipid abnormalities
Table 2 describes lipid proﬁle in all patients with any data
available (lower panel) and in patients for which all three val-
ues (LDL–C, HDL–C and TG) were available (total lipid pro-
ﬁle). Among patients with a total lipid proﬁle available
(n= 1,239), LDL–C levels were not at target in 67.2%. Low
HDL–C levels were observed in 46.9% and elevated triglycer-
ide levels in 37.3%. Assessment by CVD risk status demon-
strated that LDL–C not at target was more common inhigh- and very-high risk patients (both 72%) than in moder-
ate-risk patients (50%). The frequency of elevated triglyceride
levels was similar across the risk groups, ranging from 28.9%
to 39.3%. Low HDL–C levels were present in 48.0% of
very-high risk patients and approximately 40% of low-, mod-
erate- and high-risk patients. Kernel density curves of total
cholesterol, LDL–C, HDL–C in men and women, and triglyc-
eride levels are presented in Fig. 2.
Sub-group analyses indicated that low HDL–C and ele-
vated triglyceride levels were most common in patients with
both CVD and diabetes mellitus (49.8% and 43.8%, respec-
tively in those with a total lipid proﬁle), while LDL–C levels
not at target were most prevalent in patients with a SCORE
risk ofP10% (76.0%) and diabetes mellitus (75.5%; Table 3).
Distributions of single and multiple combined lipid abnor-
malities in patients with a total lipid proﬁle, non-very high and
very-high risk patients are illustrated in Fig. 3. Among patients
with a total lipid proﬁle, 14.9% had no lipid abnormalities and
15.8% had all three lipid abnormalities. Among non-very high
risk and very-high risk patients, 28.8% and 12.3%, respec-
tively, had no lipid abnormalities, and 9.9% and 16.9%,
respectively, had all three lipid abnormalities. In very high-risk
patients, the most common dual lipid abnormality was above-
target LDL–C levels combined with low HDL–C levels
(18.8%), followed by above-target LDL–C combined with ele-
vated triglycerides (11.7%), and low HDL–C levels combined
with elevated triglycerides (5.2%). In non-very high risk pa-
tients, the distribution of dual lipid abnormalities was less var-
iable: 9.9% for above-target LDL–C combined with either low
HDL–C or elevated triglycerides, and 8.4% for low HDL–C
levels and elevated triglycerides. Among patients with at least
one lipid abnormality, as shown in Fig. 3, all three lipid abnor-
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Figure 2 Kernel density curves of lipids. Vertical lines mark the cut point of ESC guidelines (2011).
228 A. El Etriby et al.malities were present in 18.6% of patients with a total lipid
proﬁle, 14.0% of non-very high risk patients and 19.3% of
very-high risk patients.
3.4. Factors associated with dyslipidemia
Multivariate logistical regression models were used to identify
factors independently associated with lipid abnormalities in
the study population. LDL–C levels not being at target were
strongly and positively associated with diabetes mellitus, ische-
mic heart disease, and high blood pressure. They were nega-
tively associated with a simvastatin equivalent dose of
>40 mg/day (vs. 10 mg/day), and ezetimibe treatment. The
only factor statistically signiﬁcantly associated with low
HDL–C levels was current tobacco smoking. Elevated triglyc-
eride levels were positively associated with sedentary lifestyle,
large waist circumference, and high blood pressure. They were
negatively associated with age P70 years, female gender andalcohol consumption of >2 units/week. Factors strongly asso-
ciated with all three lipid abnormalities included a positive
association with current tobacco smoking, large waist circum-
ference, sedentary lifestyle and high blood pressure and a neg-
ative association with ezetimibe (Table 4).
4. Discussion
DYSIS-Egypt demonstrated that the majority of patients were
at very high risk of CVD, and the most frequent lipid abnor-
mality was LDL–C levels not at target. Above-target LDL–
C levels were found in 72% of both high- and very-high risk
patients, declining to 50% for moderate-risk patients. Overall,
LDL–C levels were not at target in 67% of patients, a higher
proportion than in the Canadian and European (48%), and
Middle-Eastern (62%) cohorts of the DYSIS study. In con-
trast to the Canadian/European cohort, in which above-target
LDL–C levels were more common in low-risk as opposed to
Table 3 Lipid abnormalities according to ESC guidelines (2011) in very high risk patients.
Patients with total
lipid proﬁle
CVD+DM
(n= 434)
CVD (w/o DM)
(n= 377)
DM (w/o CVD)
(n= 212)
SCORE P10%
(n= 25)
LDL–C P1.8 mmol/L
and LDL–reduction
<50% [%]
72.4 68.4 75.5 76.0
Low HDL–C (<1.0 [men]/1.2
[women] mmol/L) [%]
49.8 47.5 45.8 44.0
Elevated TG
(>1.7 mmol/L) [%]
43.8 31.8 34.4 40.0
All patients (n= 526) (n= 430) (n= 255) (n= 29)
LDL–C P1.8 mmol/L
and LDL–reduction <50%
[%]a
71.9 67.5 73.7 74.1
Low HDL–C
(<1.0 [men]/1.2
[women] mmol/L) [%]b,c
48.2 45.7 43.8 44.4
Elevated TG (>1.7
mmol/L) [%]c
43.6 31.3 34.3 38.5
a Data on 1650 patients were available.
b Data on 1787 patients were available.
c Data on 1786 patients were available.
A. Non-very 
high risk 
patients (ESC 
2011, SCORE 
<10%) with at 
least one lipid 
abnormality
B. Very high 
risk patients 
(ESC 2011, 
CVD, diabetes 
and/or ESC-
SCORE ≥10%) 
with at least one 
lipid 
abnormality
C. Non-very 
high risk 
patients (ESC 
2011, SCORE 
<10%)
11.0%
(15)17.6%(24)
14.0%
(19)
14.0%
(19)
17.6%
(24)
11.8%
(16)
14.0%
(19)
LDL-C not at goal
(≥2.5/3.0 mmol/l)
Low HDL-C
(<1.0 (m) / 1.2 (w) mmol/l)
Elevated TG
(>1.7 mmol/l)
4.2%
(39)8.2%(75)
21.4%
(197)
19.3%
(177)
27.6%
(254)
5.9%
(54)
13.4%
(123)
LDL-C not at goal
(≥1.8 mmol/l + 
<50% LDL-C reduction)
Low HDL-C
(<1.0 (m) / 1.2 (w) mmol/l)
Elevated TG
(>1.7 mmol/l)
7.9%
(15)
28.8%
(55)
12.6%
(24)
9.9%
(19)
9.9%
(19)
12.6%
(24)
8.4%
(16)
9.9%
(19)
No lipid abnormalities
LDL-C not at goal
(≥2.5/3.0 mmol/l)
Low HDL-C
(<1.0 (m) / 1.2 (w) mmol/l)
Elevated TG
(>1.7 mmol/l)
Figure 3 Distribution of single and multiple combined lipid abnormalities.
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D. Very high 
risk patients 
(ESC 2011, 
CVD, diabetes 
and/or ESC-
SCORE ≥10%)
E. Patients with 
at least one lipid 
abnormality
F. Patients with 
total lipid 
profile
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(≥1.8 mmol/l + 
<50% LDL-C reduction)
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Elevated TG
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(54)9.4%(99)
20.5%
(216)
18.6%
(196)
26.4%
(278)
6.6%
(70)
13.5%
(142)
LDL-C not at goal
(≥1.8 + <50% LDL-C reduction /
≥2.5 / ≥3.0 mmol/l)
Low HDL-C
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(>1.7 mmol/l)
4.4%
(54)
14.9%
(184)
8.0%
(99)
17.4%
(216)
15.8%
(196)
22.4%
(278)
5.6%
(70)
11.5%
(142)
No lipid abnormalities
LDL-C not at goal
(≥1.8 + <50% LDL-C reduction / 
≥2.5 / ≥3.0 mmol/l)
Low HDL-C
(<1.0 (m) / 1.2 (w) mmol/l)
Elevated TG
(>1.7 mmol/l)
Fig. 3 (continued)
230 A. El Etriby et al.high-risk patients, in the Egyptian study, elevated LDL–C lev-
els were more frequent in high- and very-high risk patients
than moderate-risk patients.16,20
The prevalence of very high cardiovascular risk and inade-
quately controlled LDL–C levels in Egyptian patients may re-
ﬂect the very high rates of metabolic disorders observed.
Approximately 90% of women enrolled had metabolic syn-
drome and almost three-quarters were obese. For comparison,
in the DYSIS-Middle East study, 82% and 59% of women had
metabolic syndrome and obesity, respectively, but the overall
frequency of diabetes mellitus was lower in the Egyptian study
(55%) relative to the Middle Eastern study (67%). The overall
rate of obesity in the DYSIS-Egypt study (62%) was almost
twice that estimated by the WHO for the Egyptian population
in 2008 (33%).3
Interestingly, estimates of the prevalence of tobacco smok-
ing in the DYSIS-Egypt study were very similar to those from
the WHO, with around 20% of the Egyptian population being
tobacco smokers. In addition, both WHO ﬁgures and the
DYSIS-Egypt study indicate that most tobacco smokers in
Egypt are men (32–35% vs. 1–4% of women). In the DYSIS
Egypt-study, tobacco smoking emerged as the only factor
independently associated with low HDL–C levels. However,
at baseline, mean HDL–C levels were similar for men and wo-men (1.1 [42.57 mg/dl] and 1.2 mmol/l [46.44 mg/dl], respec-
tively). In relation to this point, there is a lack of therapeutic
options to increase HDL–C levels, as well as inconclusive evi-
dence on the beneﬁts of raising HDL–C levels with pharma-
ceutical agents.21–23 Data from the JUPITER primary
prevention study (patients with a baseline LDL–C
<3.37 mmol/l and high-sensitivity C-reactive protein of
2 mg/L or more randomized to rosuvastatin or placebo) indi-
cate that HDL–C levels do not contribute to residual cardio-
vascular risk in patients on statin treatment who attain very
low concentrations of LDL–C.24,25
The only factor with a positive association with reaching all
three lipid targets was the use of ezetimibe. Female gender,
simvastatin use (>40 vs. 10 mg/day) and ezetimibe use had a
positive association with reaching LDL–C goals. The effects
of statin treatment have been assessed in several studies. The
JUPITER study results demonstrated that statins are beneﬁ-
cial for cardiovascular risk reduction, both in individuals with
and without risk factors for diabetes mellitus.15 Up-to-date
guidelines on the prevention and management of CVD in dif-
ferent patient populations have been published very recently
by the ESC.26 Our data suggest that statin doses used are gen-
erally low (40.4% of those with on-very high risk, 31.1% of
very high risk patients received a statin dose equivalent to
Table 4 Factors independently associated with LDL–C, HDL–C, and triglyceride (TG) abnormalities: results of multivariable logistic
regression (OR (95% CI)).
LDL–C not at target*
(P1.8/2.5/3.0 mmol/L)
Low HDL–C*
(<1.0 (m)/1.2
(w) mmol/L)
Elevated TG*
(>1.7 mmol/L)
LDL–C not at target and low
HDL–C and elev. TG*
Age P70 years n.s. n.s. 0.43 (0.28–0.67) n.s.
Female 0.65 (0.47–0.89) n.s. 0.65 (0.50–0.85) n.s.
Current smoker n.s. 1.32 (1.01–1.71) n.s. 1.51 (1.06–2.16)
Sedentary lifestyle n.s. n.s. 1.55 (1.18–2.05) n.s.
Alcohol consumption >2 units/week n.s. n.s. 0.30 (0.10–0.90) n.s.
WC >102 (m) />88 cm (w) n.s. n.s. 1.69 (1.28–2.22) 1.71 (1.20–2.43)
Diabetes mellitus 2.30 (1.69–3.13) n.s. n.s. n.s.
Ischemic heart disease 1.64 (1.18–2.27) n.s. n.s. n.s.
BP P140/90 mmHg (systolic/diastolic) 1.95 (1.44–2.65) n.s. 1.68 (1.32–2.13) 1.43 (1.03–1.97)
Simvastatin >40 vs. 10 mg/day 0.32 (0.22–0.46) n.s. n.s. n.s.
Ezetimibe 0.01 (0.00–0.01) n.s. n.s. 0.08 (0.03–0.22)
Backward selection (alpha = 0.05) was performed.
Abbreviations: m, men; w, women; BP, blood pressure; n.s., not signiﬁcant (p> 0.05); OR, odds ratio; CI, conﬁdence interval.
* Models contained the following variables: age, sex, 1st grade family history of premature CVD, current smoker, sedentary lifestyle, alcohol
consumption >2 units/week, BMI P30 kg/m2 (obesity), waist circumference >102 cm in men/>88 cm in women, hypertension, diabetes
mellitus, ischemic heart disease, cerebrovascular disease, heart failure, peripheral artery disease, RRP140/90 mmHg (systolic/diastolic), 20–40
vs. 10 mg/day Simvastatin equivalent, P80 vs. 10 mg/day Simvastatin equivalent.
Egyptian patients on chronic statin treatment 23120 mg) and increasing their dose as well as combination ther-
apy might result in a further improvement of lipid treatment
goal achievement.
Limitations of the DYSIS study include its cross-sectional
design. Since data were collected at a single time-point, this
precludes both the assessment of long-term outcomes as well
as drawing any conclusions on the temporal relationship of
associations observed. Central analysis of lipid levels was not
possible because blood samples were not obtained speciﬁcally
for the DYSIS study, and, in addition, data on lipid levels
prior to initiation of statin treatment were not available. Be-
cause blood samples for lipid analysis were taken up to
6 months prior to baseline, but patients only had to be receiv-
ing stable statin treatment for 3 months, it is possible that pa-
tients’ treatment regimens could have been modiﬁed. Finally
the patient population under investigation did not include
those with acute coronary syndromes or advanced heart fail-
ure, which calls for further studies in this group of very high
risk patients. Nevertheless, the DYSIS-Egypt study provides
an up-to-date clinical perspective on the characteristics and po-
tential predictors of lipid abnormalities in Egyptian patients on
chronic statin treatment.
5. Conclusions
The DYSIS-Egypt study demonstrates that, despite the in-
creased awareness of Egyptian patients about the risks of dysl-
ipidemia and the need for improved guideline adherence, only
one third of very high risk patients reaches treatment targets.
In comparison, in Egypt, a lower proportion of patients at-
tained LDL–C goals than in the other DYSIS cohorts, and
rates of tobacco smoking in men and metabolic disorders in
women were very high.
This results in the situation that the majority of patients re-
main at very high risk of CVD because of either suboptimal
statin dosing or the under use of combination therapy. Based
on this evidence, there is an urgent requirement for increasedawareness of the impact of lifestyle choices on cardiovascular
risk, as well as for the development of new therapeutic options
to allow successful management of cardiovascular risk in very-
high risk patients.
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